Survival of young and older breast cancer patients in Geneva from 1990 to 2001

Rapiti, Elisabetta; Fioretta, G; Verkooijen, Helena M.; Vlastos, Georges; Schäfer, Peter; Sappino, André‐Pascal; Kurtz, John M.; Neyroud-Caspar, Isabelle; Bouchardy, Christine

doi:10.1016/j.ejca.2005.02.029

Cited by 81 publications

(74 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A Swiss study investigating cause-specific BC survival found no survival differences between younger and older women. Although in this study younger Swiss women, consistent with other international studies, were diagnosed with more advanced and aggressive tumours [20].…”

Section: Introductionsupporting

confidence: 91%

Breast cancer in younger women in Switzerland 1996–2009: A longitudinal population-based study

et al. 2015

Self Cite

View full text Add to dashboard Cite

a b s t r a c tBackground: Breast cancer (BC) is the most commonly diagnosed cancer and a leading cause of death in younger women. Methods: We analysed incidence, mortality and relative survival (RS) in women with BC aged 20 e49 years at diagnosis, between 1996 and 2009 in Switzerland. Trends are reported as estimated annual percentage changes (EAPC). Results: Our findings confirm a slight increase in the incidence of BC in younger Swiss women during the period 1996e2009. The increase was largest in women aged 20e39 years (EAPC 1.8%). Mortality decreased in both age groups with similar EAPCs. Survival was lowest among women 20e39 years (10-year RS 73.4%). We observed no notable differences in stage of disease at diagnosis that might explain these differences. Conclusions: The increased incidence and lower survival in younger women diagnosed with BC in Switzerland indicates possible differences in risk factors, tumour biology and treatment characteristics that require additional examination.

show abstract

Section: Introductionsupporting

confidence: 91%

Breast cancer in younger women in Switzerland 1996–2009: A longitudinal population-based study

et al. 2015

Self Cite

View full text Add to dashboard Cite

show abstract

“…17 Diğer taraftan, Singapur'da yapılan retrospektif bir çalışmada, genç yaştaki meme kanserli hastaların sağkalım oranlarının, daha ileri yaştaki hastalara oranla daha iyi olduğu; İsveç'te yapılan diğer bir çalışmada da genç yaşın sağkalıma etkisinin olmadığı belirtilmektedir. 19,20 Van de Vijver ve ark. çalışmalarında, gen sunumu profilinin, genç meme kanseri hastalarında güçlü bir prognostik faktör olduğunu, fakat yaşın bağımsız bir risk faktörü olmadığını göstermişlerdir.…”

Section: Discussionunclassified

Clinical and Histopathologic Characteristics of Breast Cancer Cases Aged 35 Years and Younger

Soyder¹,

Özbaş²,

Koçak³

2013

Turkiye Klinikleri J Med Sci

View full text Add to dashboard Cite

Ö ÖZ ZE ET T A Am ma aç ç: : Meme kanserinin genç hastalarda daha agresif seyrettiği, daha yüksek mortalite ve nüks oranına sahip olduğu öne sürülmektedir. Çalışmamızda, meme kanseri tanısı ile tedavi ve takip edilen 35 yaş ve altındaki olguların tanı anındaki klinik ve histopatolojik özellikleri ile uygulanan tedavilerin ve takip sonuçlarının değerlendirilmesi hedeflendi. G Ge er re eç ç v ve e Y Yö ön nt te em ml le er r: : Çalışmaya iki ayrı merkezde Haziran 2004-Temmuz 2011 tarihleri arasında meme kanseri tanısı nedeniyle ameliyat edilen toplam 522 hastadan, tanı anında 35 yaş ve altında olan 88 olgu dâhil edildi. Hastalara ait klinik ve histopatolojik özellikler, uygulanan tedaviler ve takip sonuçları geriye dönük olarak incelendi ve elde edilen veriler tanımlayıcı olgu serisi şeklinde raporlandı. B Bu ul lg gu ul la ar r: : Otuz beş yaş ve altındaki olgular tüm meme kanserli olgularımızın %16,9'unu oluşturmaktaydı. Olguların 58'inin (%65,9) tanı sırasında Evre 0, I ve II olduğu, 67'sinde (%76,1) lenfovasküler invazyon bulunduğu ve 46'sında (%52,2) tümörün derece 2 olduğu görüldü. Olguların 51'inde (%57,9) östrojen reseptörü pozitif ve 33'ünde (%37,5) progesteron reseptörü pozitif saptandı. CerbB-2 29 (%32,9) olguda pozitifti. Elli iki (%59,1) olguda aksiller lenf düğümü tutulumu saptandı. Otuz sekiz (%43,2) olguya meme koruyucu cerrahi ve 50 (%56,8) olguya mastektomi uygulandı. Mastektomiden sonra olguların 23'ünde (%46) eş zamanlı meme rekonstrüksiyonu tercih edildi. Toplam 26,9 ± 18,77 (11-72) aylık takipte 2 (%2,3) olguda meme kanserine özgül mortalite görülürken, lokal nüks izlenmedi. S So on nu uç ç: : Otuz beş yaş ve altındaki meme kanserli olgu grubunda kötü prognostik özelliklerin yüksek oranda bulunduğu dikkati çekmektedir. Bunun yanında, hastalıksız sağkalım oranının yüksek ve lokal nüks oranlarının düşük olması sevindiricidir. Ayrıca, genç yaşta meme kanseri ortaya çıkan, kadınlarda mastektomi gerektiren durumlarda, eş zamanlı meme rekonstrüksiyonu uygulamasının mutlaka değerlendirilmesi gerektiği görüşündeyiz.A An na ah ht ta ar r K Ke el li im me el le er r: : Meme tümörleri; genç erişkin; prognoz; sağkalım A AB BS ST TR RA AC CT T O Ob bj je ec ct ti iv ve e: : Breast cancer is reported to progress more aggressively and to have a higher mortality and relapse rate in younger patients. In this study, clinical and histopathologic characteristics and treatment options will be assessed in breast cancers in patients 35 years and younger. M Ma at te er ri ia al l a an nd d M Me et th ho od ds s: : The study included 88 cases aged 35 years and younger out of 522 cases operated with for breast cancer between June 2004 and July 2011. Clinical and histopathologic characteristics, treatment modalities and follow-up results were analyzed retrospectively. R Re es su ul lt ts s: : Cases aged 35 years and younger accounted for 16.9% of all breast cancer cases. By the time of diagnosis 58 (65.9%) cases were Stage 0, I and II, 67 (76.1%) had lymphovascular invasion and 46 (52.2%) had Grade 2 tumor. Estrogen re...

show abstract

“…Since the late 1990s, several studies have demonstrated the importance of adjuvant chemotherapy among young breast cancer patients by showing that the unfavourable impact of young age on breast cancer survival is valid only among patients treated without chemotherapy, and that among women treated with chemotherapy, young age is no longer an independent prognostic risk factor (Greenberg et al, 1985;Kroman et al, 2000;Rapiti et al, 2005). In this study, we show that young breast cancer patients without axillary lymph node involvement were more likely to be treated with chemotherapy, hormonotherapy or both, if they had a strong family history of breast or ovarian cancer.…”

Section: Discussionmentioning

confidence: 99%

Impact of familial risk factors on management and survival of early-onset breast cancer: a population-based study

et al. 2005

View full text Add to dashboard Cite

This population-based study evaluates the impact of a strong family history of breast cancer on management and survival of women with early-onset disease. We identified all breast cancer patients p50 years, recorded between 1990 and 2001 at the Geneva familial breast cancer registry. We compared patients at high familial risk and low familial risk in terms of tumour characteristics, method of detection, treatment, survival and breast cancer mortality risk. Compared to patients at low familial risk (n ¼ 575), those at high familial risk (n ¼ 58) received significantly more often systemic therapy, especially for node-negative or receptor-positive disease. Five-year disease-specific survival rates of patients at high vs low familial risk were 86 and 90%, respectively. After adjustment, there was no difference in breast cancer mortality in general. A strong family history nonsignificantly increased breast cancer mortality in patients p40 years (adjusted hazard ratio (HR) 4.0, 95% CI 0.8 -19.7) and in patients treated without chemotherapy (adjusted HR 2.7, 95% CI 0.6 -12.5). A strong family history of breast cancer is associated with an increased use of systemic therapy in early-onset patients. Although a strong family history does not seem to affect survival in general, it may impair survival of very young patients and patients treated without adjuvant chemotherapy. Owing to the limited number of patients in this study, these results should be used only to generate hypotheses.

show abstract

Survival of young and older breast cancer patients in Geneva from 1990 to 2001

Cited by 81 publications

References 19 publications

Breast cancer in younger women in Switzerland 1996–2009: A longitudinal population-based study

Breast cancer in younger women in Switzerland 1996–2009: A longitudinal population-based study

Clinical and Histopathologic Characteristics of Breast Cancer Cases Aged 35 Years and Younger

Impact of familial risk factors on management and survival of early-onset breast cancer: a population-based study

Contact Info

Product

Resources

About